{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-26-069512","form_type":"8-K","ticker":"LABT","cik":"0002079272","company_name":"Lakewood-Amedex Biotherapeutics Inc.","filed_at":"2026-06-17T15:40:39+00:00","discovered_at":"2026-06-17T15:42:00.268736+00:00","generated_at":"2026-06-17T15:42:10.178847+00:00","sec_items":["3.03","5.03","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Lakewood-Amedex announces 1-for-10 reverse stock split effective June 19, 2026","bullets":["Reverse split ratio: 1-for-10; effective at 4:01 p.m. ET on June 19, 2026; trading starts split-adjusted on Nasdaq June 22.","Outstanding shares reduced from ~17,506,577 to ~1,750,789; fractional shares rounded up to next whole share.","Authorized shares reduced proportionately to 12,500,000; new CUSIP 51255A201 assigned; ticker LABT unchanged.","Board unanimously approved the split on June 1, 2026; adjustments made to equity awards, warrants, and preferred stock.","No stated reason for the split; typical use is to regain Nasdaq minimum bid price compliance."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-069512","json":"https://secwatch.observer/filing/0001213900-26-069512.json","markdown":"https://secwatch.observer/filing/0001213900-26-069512.md","text":"https://secwatch.observer/filing/0001213900-26-069512.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/2079272/000121390026069512/0001213900-26-069512-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2079272/000121390026069512/ea0294845-8k_lakewood.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-17T15:42:10.178847+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"c1add010a37a2882c0e1d53ec4ca66cbbcddfc6f","claim":"Lakewood-Amedex Biotherapeutics Inc.: Filed a Certificate of Change to effectuate a 1-for-10 reverse stock split and reduce authorized shares to 12,500,000 (effective 2026-06-19).","evidence_excerpt":"On June 15, 2026, Lakewood-Amedex Biotherapeutics Inc (the “Company”) filed a Certificate of Change (the “Certificate of Change”) with the Secretary of State of the State of Nevada to effectuate a 1-for-10 reverse stock split (the “Reverse Stock Split”) of the Company’s issued and outstanding and authorized shares of common stock, par value $0.0001 per share (“Common Stock”).","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/2079272/000121390026069512/0001213900-26-069512-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"charter amendment"},{"label":"Effective","value":"2026-06-19"}],"fact_type":"governance_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}